176: Phase I/II Trial of Bortezomib Maintenance following Autologous Peripheral Blood Progenitor Cell Transplantation as Treatment for Intermediate- and Advanced-Stage Multiple Myeloma  by Schiller, G.J. et al.
Poster Session I 65Of note, among these 23 pts, 11 are alive at a median of
40.5 months (range 13.5–91) after relapse. Two of these patients
subsequently underwent a nonmyeloablative transplant and are
alive - one at 51.7 months and the other at 18.7 months after non-
myeloablative transplant. The nine other pts have received a spec-
trum of chemotherapy agents after relapse. Conclusion: ASCT is
a safe and effective strategy in the management of MCL. The en-
couraging results observed for pts undergoing ASCT in first remis-
sion merit further prospective evaluation. A subset of pts tends to
have a prolonged survival despite relapsing after ASCT. The clinical
characteristics pre and post ASCT do not reveal an obvious cause
for the same. It is likely that the ongoing work in gene expression
profiling and study of signaling pathways may identify multiple mo-
lecularly and clinically distinct diseases within what is considered
a single disease entity.
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LONG TERM FOLLOW-UP REPORT ON AUTOLOGOUS STEM CELL
TRANSPLANT (ASCT) FOR MULTIPLE MYELOMA (MM) AND EVALUA-
TION OF PROGNOSTIC FACTORS: PROLONGED SURVIVAL FOR PATIENTS
WITH LOW HEAMTOPOIETIC CELL TRANSPLANTATION-COMORBITD-
ITY INDEX (HCT-CI) SCORE
Farhat,M., Kassar,M., Gregory, S.A., Venugopal, P.,Myint, R., Go, A.,
Maciejewski, J., Fung, H.C. Rush University Medical Center, Chicago,
IL.
Background: Up-front ASCT is the standard of care for eligible
patients with symptomatic MM. However, there is a lack of long
term follow up data on patient with multiple myeloma from time
of diagnosis. Objective: Evaluation of prognostic factors including
the HCT-CI on mortality risk after autologous stem cell transplant
(ASCT) in multiple myeloma (MM).Methods:We conduct a retro-
spective analysis on 79 patients (pts) with multiple myeloma whom
been followed since original diagnosis between 01/1983 to 12/2003.
The median time from diagnosis to ASCT was 7.6 months. All of
which underwent ASCT in our institution with a median follow
up after ASCT of 45 months. All pts received with induction che-
motherapy before ASCT consisting of various combinations of vin-
cristine, adriamycin, dexamethasone, thalidomide, melphalan,
BCNU, and cyclophospamide. The median CD34 cells collected
was 5.05  106/Kg, with a median hospital stay at transplant of 17
days. Pts were also retrospectively assigned scores based on the
HCT-CI. Definitions of comorbidities were previously reported
(Sorror et. al. Blood 2005; 106:2912). Results: The group com-
prised 50% male with a median age was 55 years (38 – 73). 55 pts
had single transplant and 24 pts had a tandem ASCT. The majority
of pts had IgG myeloma (62 pts.). Comorbidities index showed an
HCT-CI score of 0 in 30%, 1 in 30%, 2–8 in 40% of the pts,
with a median score of 1.77. 20 patients died with only one due to
treatment related mortality (TRM). Pts were categorized into 2
groups: low-risk (scores of 0–1), 46 pts. High-risk (scores 2–8), 33
pts. Neither age, gender, hospital during at transplant, prior
chemo-regimen, or pre-conditioning regiment, amount of CD34
cell collected, nor myeloma subtype, had an significant impact on
OS. By using Kaplan meier survival estimates, the 5 yrs overall sur-
vival (OS) from time of diagnosis comparing the low risk and high
risk group using the HCT-CI, were 82% and 53% respectively (P
5 0.03). Using a cox regression model, the low risk group has a sur-
vival advantage (HR5 2.69, P5 0.03). The median OS for the high
risk group was 63.7 month while it was not reached for the low risk
group. Conclusion: We conclude that in this cohort with adequate
follow-up: 1) HCT-CI score is the only predictive factor for survival
irrespective of other compounding factors and 2) prolonged survival
can be achieved in the subgroup of pts with low HCT-CI score.
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PHASE I/II TRIAL OF BORTEZOMIB MAINTENANCE FOLLOWING AUTOL-
OGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION AS
TREATMENT FOR INTERMEDIATE- AND ADVANCED-STAGE MULTIPLE
MYELOMA
Schiller, G.J., Liao, M., Sohn, J.P., Malone, R., Bartoni, K.,
Habtemariam, B., Paquette, R., De Vos, S., Territo, M. University of
California, Los Angeles, Los Angeles, CA.Pts with intermediate- and advanced-stage multiple myeloma
were assigned to maintenance therapy with bortezomib beginning
a minimum of 3 and a maximum of 4 mos after the day of autologous
PBPC transplantation following a standard preparative regimen of
high-dose melphalan. Eligibility for the initiation of maintenance
required nl organ function with post-transplant neutrophil and plt
recovery. Cohorts of 3 pts each were entered at 1 of 3 dose levels
of bortezomib (1.0, 1.3, and 1.6 mg/m2) given IV q wk for 3 wks fol-
lowed by a 1-wk rest period constituting 1 treatment cycle for a total
of 8 cycles. To-date, 29 pts were eligible for study treatment and 23
pts received at least 1 dose of maintenance. The median t from di-
agnosis to transplant was 11.4 mos and the median t from autolo-
gous transplant to the initiation of bortezomib maintenance was
3.7 mos. Protocol adherence was excellent with only 1 pt missing
the final dose of treatment and 1 other pt discontinuing therapy
due to personal reasons. After completion of the Phase I portion
of the study, the DLT was determined to be 1.6 mg/m2 based on
grade 3 diarrhea in 2 pts. All subsequent pts entered were treated
at the MTD of 1.3 mg/m2. Other, non-dose-limiting toxicities in-
cluded thrombocytopenia, neuropathy, anemia, fatigue, neutrope-
nia, musculoskeletal pain, nausea, herpes zoster reactivation,
diarrhea, edema, and cough. Disease assessment consisted of serum
and urine PEP and bone surveys as well as bone marrow aspiration
for those pts with nonsecretory myeloma. 2 pts required termina-
tion of the study drug due to unacceptable side effects. 2 separate
pts terminated the study due to disease progression. 1 additional
pt discontinued further study treatments due to personal reasons.
All 23 pts are eligible for response assessment. 13 pts continue to
be followed for disease recurrence in the post-treatment period
while 4 others continue on treatment. After a median follow-up
from transplantation of 17.1 mos, 6 pts have relapsed while none
have died of recurrent myeloma. The current median relapse-free
survival is 15.8 mos. This phase I/II trial demonstrates that bortezo-
mib can be safely administered as maintenance after conventional
autologous PBPC transplantation with an MTD of 1.3 mg/m2 given
3 times per month for 8 mos. These preliminary results, when com-
pared to published results of autologous transplantation for mye-
loma, suggest that bortezomib maintenance may favorably impact
t-to-recurrence.177
THE ‘‘SIDE-POPULATION’’ IN HUMAN LYMPHOMA CELL LINES HAVE IN-
CREASED CHEMO-RESISTANCE, STEM-LIKE PROPERTIES, AS A TARGET
FOR IMMUNOTHERAPY
Shafer, J.A.1,2, Bollard, C.M.1,2, Leen, A.M.1,2, Rooney, C.M.1,2,
Brenner, M.K.1,2, Foster, A.E.1,2. 1Baylor College of Medicine; 2Baylor
College of Medicine, Houston, TX.
We previously demonstrated that cancer cells contain a distinct
‘‘side-population’’ (SP), characterized by active transport of
Hoechst fluorescent dye. The mechanisms responsible for Hoechst
efflux also contribute to resistance to chemotherapy. This popula-
tion has been shown to be enriched for tumor initiating cells in sev-
eral human cancer models. We hypothesize that targeting the
cancer ‘‘SP’’ cells using immunotherapy will eliminate the cell pop-
ulation least sensitive to chemotherapy and enriched for tumor re-
populating potential which may prevent relapse. In this study we
characterize SP cells in ten Human Lymphoma Cell Lines. We
show that that 5 of the 10 lymphoma cell lines tested (HDLM2,
L428, Ramos, Toledo, Karpas) had a distinct SP ranging from
0.8–2%. In vitro these SP cells can repopulate both the SP and
non-SP cells. Gene expression analysis of the SP showed increased
expression of ABCG2 and other ABC transporters that mediate
both the transport of Hoechst dye and other drugs including
some chemotherapeutic agents out of the cell. Further, we demon-
strated that cell lines with a SP are resistant to the chemotherapeutic
drug gemcitabine, and within these lines it the SP cells that are pref-
erentially resistant to this agent. The cell lines that did not have SP
showed either complete or partial sensitivity to this drug. In addi-
tion, we demonstrated that the SP population is enriched for the
cancer testis antigen’s MAGE-4, SSX2 and NY-ESO. These anti-
gens are attractive targets for cytotoxic T lymphocyte therapy since:
they are immunogenic, have restricted expression in normal tissues,
and are expressed in many cancers. These tumor antigens may
